Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Researchers at the University of Minnesota in the US have initiated a clinical trial to asses anti-malaria drug, hydroxychloroquine, a generic and derivative of chloroquine, to fight Covid-19.
According to Reuters, the medication is also being assessed in China, Australia and France. Last month, China National Center for Biotechnology Development reported that chloroquine phosphate demonstrated ‘certain curative effect’ with ‘fairly good efficacy’ in clinical studies.
Hydroxychloroquine is said to have a direct antiviral effect, as well as suppresses the generation of proteins linked to the inflammatory complications of various viral diseases.